KR20240049337A - Gdf15 융합 단백질 및 이의 용도 - Google Patents

Gdf15 융합 단백질 및 이의 용도 Download PDF

Info

Publication number
KR20240049337A
KR20240049337A KR1020247009488A KR20247009488A KR20240049337A KR 20240049337 A KR20240049337 A KR 20240049337A KR 1020247009488 A KR1020247009488 A KR 1020247009488A KR 20247009488 A KR20247009488 A KR 20247009488A KR 20240049337 A KR20240049337 A KR 20240049337A
Authority
KR
South Korea
Prior art keywords
seq
fusion protein
amino acid
gdf15
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247009488A
Other languages
English (en)
Korean (ko)
Inventor
지앙위 얀
롱보 차오
린 시아오
준난 정
리메이 후앙
시링 웨이
자오펑 리
칭웨이 공
싱구오 얀
징 리
단시아 후앙
시아오펑 천
웬지아 리
Original Assignee
선샤인 레이크 파르마 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선샤인 레이크 파르마 컴퍼니 리미티드 filed Critical 선샤인 레이크 파르마 컴퍼니 리미티드
Publication of KR20240049337A publication Critical patent/KR20240049337A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247009488A 2021-08-24 2022-08-23 Gdf15 융합 단백질 및 이의 용도 Pending KR20240049337A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110977378 2021-08-24
CN202110977378.7 2021-08-24
PCT/CN2022/114096 WO2023025120A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
KR20240049337A true KR20240049337A (ko) 2024-04-16

Family

ID=85321545

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009488A Pending KR20240049337A (ko) 2021-08-24 2022-08-23 Gdf15 융합 단백질 및 이의 용도

Country Status (8)

Country Link
US (3) US20240391971A1 (https=)
EP (3) EP4393940A4 (https=)
JP (1) JP2024532882A (https=)
KR (1) KR20240049337A (https=)
CN (3) CN115925983A (https=)
AU (1) AU2022333099A1 (https=)
CA (1) CA3226178A1 (https=)
WO (3) WO2023025120A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CA2919076C (en) * 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CR20200510A (es) * 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
PE20221316A1 (es) * 2019-10-15 2022-09-07 Dragonfly Therapeutics Inc Proteinas que se unen a nkg2d, cd16 y flt3
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
JP2025504612A (ja) * 2021-12-31 2025-02-13 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用

Also Published As

Publication number Publication date
EP4393941A1 (en) 2024-07-03
EP4393941A4 (en) 2025-10-15
EP4392461A1 (en) 2024-07-03
CN115925983A (zh) 2023-04-07
JP2024532882A (ja) 2024-09-10
CN115925984A (zh) 2023-04-07
WO2023025123A1 (zh) 2023-03-02
AU2022333099A1 (en) 2024-02-08
EP4392461A4 (en) 2025-10-15
WO2023025129A1 (zh) 2023-03-02
EP4393940A4 (en) 2025-10-15
EP4393940A1 (en) 2024-07-03
US20240343770A1 (en) 2024-10-17
US20240350588A1 (en) 2024-10-24
CA3226178A1 (en) 2023-03-02
WO2023025120A1 (en) 2023-03-02
US20240391971A1 (en) 2024-11-28
CN115925982A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
EP3144320B1 (en) Fc fusion proteins comprising novel linkers or arrangements
KR102668200B1 (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
JP2020509761A (ja) 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
US20220017584A1 (en) Growth differentiation factor 15 fusion proteins
JP2015527974A (ja) 線維芽細胞増殖因子２１タンパク質
WO2018032787A1 (zh) 高糖基化人生长激素融合蛋白及其制备方法与用途
CN114591415B (zh) Glp-1/gcg双受体激动剂多肽及其融合蛋白
WO2023280133A1 (zh) 融合蛋白及其应用
TWI889865B (zh) 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途
CN116568711A (zh) 一种人glp-1多肽变体及其应用
KR20240126875A (ko) Glp-1과 gdf15의 융합 단백질 및 이의 용도
KR20240049337A (ko) Gdf15 융합 단백질 및 이의 용도
WO2022143515A1 (zh) 一种人glp-1多肽变体及其应用
US11667689B2 (en) Insulin-Fc fusion proteins and methods of use to treat cancer
WO2026039359A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039340A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039341A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
US20090270325A1 (en) Growth factor
HK1045160A (en) Expression and export of anti-obesity proteins as fc fusion proteins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000